Список литературы
1.
Савченко В.Г., Паровичникова Е.Н. Острые лейкозы // Клиническая
онкогематология: руководство для врачей. Под ред. Волковой М.А.. 2-е изд.,
перераб. и доп. 2007. P. 409–502.
2.
Паровичникова Е.Н. et al. Клинический протокол ОМЛ-01.10 по лечению острых
миелоидных лейкозов взрослых // Программное лечение заболеваний крови, под
ред. Савченко В.Г. М.: Практика, 2012. P. 153–207.
3.
Shallis R.M. et al. Epidemiology of acute myeloid leukemia: Recent progress and
enduring challenges. // Blood Rev. 2019. Vol. 36. P. 70–87.
4.
Swerdlow S.H. et al. The 2016 revision of the World Health Organization classification of
lymphoid neoplasms // Blood. 2016.
5.
Arber D.A. et al. The 2016 revision to the World Health Organization classification of
myeloid neoplasms and acute leukemia // Blood. 2016.
6.
Grimwade D., Hills R.K. Independent prognostic factors for AML outcome. //
Hematology / the Education Program of the American Society of Hematology. American
Society of Hematology. Education Program. 2009. P. 385–395.
7.
Döhner H. et al. Diagnosis and management of AML in adults: 2017 ELN
recommendations from an international expert panel // Blood. 2017. Vol. 129, № 4. P.
424–447.
8.
Acute Myeloid Leukemia. National Comprehensive Cancer Network (NCCN) Guidelines.
2-2020. [Electronic resource]. URL:
https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf.
9.
Kulsoom B. et al. Clinical presentation of acute myeloid leukaemia - A decade-long
institutional follow-up. // J. Pak. Med. Assoc. 2017. Vol. 67, № 12. P. 1837–1842.
10.
Godley L.A. Inherited predisposition to acute myeloid leukemia. // Semin. Hematol. 2014.
Vol. 51, № 4. P. 306–321.
11.
Oken M.M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology
Group // Am. J. Clin. Oncol. 1982. Vol. 5, № 6. P. 649–655.
12.
Roila F. et al. Intra and interobserver variability in cancer patients’ performance status
assessed according to Karnofsky and ECOG scales // Ann. Oncol. Oxford University
Press (OUP), 1991. Vol. 2, № 6. P. 437–439.
13.
Wass M. et al. Value of different comorbidity indices for predicting outcome in patients
with acute myeloid leukemia // PLoS One. 2016. Vol. 11, № 10. P. e0164587.
14.
Mohammadi M. et al. The impact of comorbid disease history on all-cause and cancer-
specific mortality in myeloid leukemia and myeloma - a Swedish population-based study.
65
// BMC Cancer. 2015. Vol. 15. P. 850.
15.
Agis H. et al. A comparative study on demographic, hematological, and cytogenetic
findings and prognosis in acute myeloid leukemia with and without leukemia cutis. // Ann.
Hematol. 2002. Vol. 81, № 2. P. 90–95.
16.
Avni B. et al. Clinical implications of acute myeloid leukemia presenting as myeloid
sarcoma. // Hematol. Oncol. 2012. Vol. 30, № 1. P. 34–40.
17.
Döhner H. et al. Diagnosis and management of acute myeloid leukemia in adults:
Recommendations from an international expert panel, on behalf of the European
LeukemiaNet // Blood. 2010. Vol. 115, № 3. P. 453–474.
18.
Ku G.H. et al. Venous thromboembolism in patients with acute leukemia: Incidence, risk
factors, and effect on survival // Blood. 2009. Vol. 113, № 17. P. 3911–3917.
19.
Lahoti A. et al. Predictors and outcome of acute kidney injury in patients with acute
myelogenous leukemia or high-risk myelodysplastic syndrome // Cancer. 2010. Vol. 116,
№ 17. P. 4063–4068.
20.
Fang R.C., Aboulafia D.M. HIV infection and myelodysplastic syndrome/acute myeloid
leukemia // HIV-Associated Hematological Malignancies. 2016. P. 133–144.
21.
Freeman A.J. et al. Estimating progression to cirrhosis in chronic hepatitis C virus
infection. // Hepatology. 2001. Vol. 34, № 4 Pt 1. P. 809–816.
22.
Ribas A. et al. How important is hepatitis C virus (HCV)-infection in persons with acute
leukemia? // Leuk. Res. 1997. Vol. 21, № 8. P. 785–788.
23.
Lam M.T. et al. Herpes simplex infection in acute myelogenous leukemia and other
hematologic malignancies: a prospective study. // Cancer. 1981. Vol. 48, № 10. P. 2168–
2171.
24.
Bernson E. et al. Cytomegalovirus serostatus affects autoreactive NK cells and outcomes
of IL2-based immunotherapy in acute myeloid leukemia // Cancer Immunol. Res.
American Association for Cancer Research Inc., 2018. Vol. 6, № 9. P. 1110–1119.
25.
Guan H. et al. Correlations between Epstein-Barr virus and acute leukemia // J. Med.
Virol. John Wiley and Sons Inc., 2017. Vol. 89, № 8. P. 1453–1460.
26.
Elmaagacli A.H., Koldehoff M. Cytomegalovirus replication reduces the relapse incidence
in patients with acute myeloid leukemia // Blood. American Society of Hematology, 2016.
Vol. 128, № 3. P. 456–459.
27.
Averbuch D. et al. Targeted therapy against multi-resistant bacteria in leukemic and
hematopoietic stem cell transplant recipients: Guidelines of the 4th European conference
on Infections in Leukemia (ECIL-4, 2011) // Haematologica. 2013. Vol. 98, № 12. P.
1836–1847.
66
28.
Averbuch D. et al. European guidelines for empirical antibacterial therapy for febrile
neutropenic patients in the era of growing resistance: Summary of the 2011 4th European
Conference on Infections in Leukemia // Haematologica. 2013. Vol. 98, № 12. P. 1826–
1835.
29.
Leahy M.F., Mukhtar S.A. From blood transfusion to patient blood management: a new
paradigm for patient care and cost assessment of blood transfusion practice. // Intern.
Med. J. 2012. Vol. 42, № 3. P. 332–338.
30.
Olsen R.J. et al. Acute leukemia immunohistochemistry: a systematic diagnostic
approach. // Arch. Pathol. Lab. Med. 2008. Vol. 132, № 3. P. 462–475.
31.
Bene M.C. et al. Proposals for the immunological classification of acute leukemias.
European Group for the Immunological Characterization of Leukemias (EGIL). //
Leukemia. 1995. Vol. 9, № 10. P. 1783–1786.
32.
Ravandi F., Walter R.B., Freeman S.D. Evaluating measurable residual disease in acute
myeloid leukemia. // Blood Adv. 2018. Vol. 2, № 11. P. 1356–1366.
33.
Лобанова Т.И., Гальцева И.В., Паровичникова Е.Н. Исследование минимальной
остаточной болезни у пациентов с острыми миелоидными лейкозами методом
многоцветной проточной цитофлуориметрии (обзор литературы) //
Онкогематология. 2018. Vol. 13, № 1. P. 83–102.
34.
Лобанова Т.И. “Клиренс опухолевого клона у пациентов с разными молекулярно-
генетическими вариантами острых миелоидных лейкозов”: диссертация ...
кандидата медицинских наук: 14.01.21. 2018. 166 p.
35.
Del Principe M.I. et al. Involvement of central nervous system in adult patients with acute
myeloid leukemia: Incidence and impact on outcome // Seminars in Hematology. W.B.
Saunders, 2018. Vol. 55, № 4. P. 209–214.
36.
Herrmann J. et al. Evaluation and management of patients with heart disease and cancer:
Cardio-oncology // Mayo Clin. Proc. 2014. Vol. 89, № 9. P. 1287–1306.
37.
Roberts A.S. et al. Extramedullary haematopoiesis: radiological imaging features //
Clinical Radiology. 2016. Vol. 71, № 9. P. 807–814.
38.
Fritz J. et al. Radiologic spectrum of extramedullary relapse of myelogenous leukemia in
adults. // AJR. Am. J. Roentgenol. 2007. Vol. 189, № 1. P. 209–218.
39.
Arrigan M. et al. Imaging findings in recurrent extramedullary leukaemias // Cancer
Imaging. 2013. Vol. 13, № 1. P. 26–35.
40.
Seegars M.B., Powell B.L., Howard D.S. Acute Myeloid Leukemia in Pregnancy // Blood.
2017. Vol. 130, № Suppl 1. P. 5035.
41.
Woitek R. et al. Radiological staging in pregnant patients with cancer // ESMO Open.
67
2016. Vol. 1, № 1. P. e000017.
42.
Cornelissen J.J. et al. The European LeukemiaNet AML Working Party consensus
statement on allogeneic HSCT for patients with AML in remission: An integrated-risk
adapted approach // Nature Reviews Clinical Oncology. 2012. Vol. 9, № 10. P. 579–590.
43.
Bertoli S. et al. Time from diagnosis to intensive chemotherapy initiation does not
adversely impact the outcome of patients with acute myeloid leukemia. // Blood. 2013.
Vol. 121, № 14. P. 2618–2626.
44.
Sekeres M.A. et al. Time from diagnosis to treatment initiation predicts survival in
younger, but not older, acute myeloid leukemia patients // Blood. 2009. Vol. 113, № 1. P.
28–36.
45.
Petti M.C. et al. High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias //
Ann. Hematol. 2003. Vol. 82, № 8. P. 476–480.
46.
Kimby E., Nygren P., Glimelius B. A Systematic Overview of Chemotherapy Effects in
Acute Myeloid Leukaemia // Acta Oncol. (Madr). 2001. Vol. 40, № 3. P. 231–252.
47.
Wang J. et al. Meta-Analysis of Randomised Clinical Trials Comparing Idarubicin +
Cytarabine with Daunorubicin + Cytarabine as the Induction Chemotherapy in Patients
with Newly Diagnosed Acute Myeloid Leukaemia // PLoS One. 2013. Vol. 8, № 4. P.
e60699.
48.
Burnett A.K. et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2in
AML induction: Results from the UK NCRI AML17 trial in 1206 patients // Blood. 2015.
Vol. 125, № 25. P. 3878–3885.
49.
Wu D. et al. Efficacy and safety of different doses of cytarabine in consolidation therapy
for adult acute myeloid leukemia patients: A network meta-analysis // Sci. Rep. 2017. Vol.
7, № 1. P. 9509.
50.
Bashir Y. et al. Role of low dose cytarabine in elderly patients with acute myeloid
leukemia: An experience // South Asian J. Cancer. Medknow, 2015. Vol. 4, № 1. P. 4.
51.
Ye X.-N. et al. Epigenetic priming with decitabine followed by low-dose
idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional
chemotherapy in high-risk myeloid neoplasms. // Leuk. Lymphoma. 2016. Vol. 57, № 6.
P. 1311–1318.
52.
Wei A.H. et al. Venetoclax Combined With Low-Dose Cytarabine for Previously
Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. // J.
Clin. Oncol. 2019. Vol. 37, № 15. P. 1277–1284.
53.
DiNardo C.D. et al. Venetoclax combined with decitabine or azacitidine in treatment-
naive, elderly patients with acute myeloid leukemia. // Blood. 2019. Vol. 133, № 1. P. 7–
68
17.
54.
Stone R.M. et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a
FLT3 Mutation // N. Engl. J. Med. 2017. Vol. 377, № 5. P. 454–464.
55.
Röllig C. et al. Addition of sorafenib versus placebo to standard therapy in patients aged
60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): A
multicentre, phase 2, randomised controlled trial // Lancet Oncol. 2015. Vol. 16, № 16. P.
1691–1699.
56.
Buchner T. et al. Long-term results in patients with acute myeloid leukemia (AML): The
influence of high-dose AraC, G-CSF priming, autologous transplantation, prolonged
maintenance, age, history, cytogenetics, and mutation status. Data of the AMLCG 1999
trial // Blood. 2009. Vol. 114, № 22. P. Abstract 485.
57.
Соколов А.Н. et al. Долгосрочные результаты лечения острых миелоидных лейкозов
у взрослых в многоцентровом клиническом исследовании ОМЛ 06.06 //
Клиническая онкогематология. 2012. Vol. 5, № 1. P. 30–38.
58.
Cornelissen J.J., Blaise D. Hematopoietic stem cell transplantation for patients with AML
in first complete remission // Blood. 2016. Vol. 127, № 1. P. 62–70.
59.
Li Z. et al. Autologous Stem Cell Transplantation Is a Viable Postremission Therapy for
Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission in the Absence
of a Matched Identical Sibling: A Meta-Analysis. // Acta Haematol. 2019. Vol. 141, № 3.
P. 164–175.
60.
Koreth J. et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first
complete remission: Systematic review and meta-analysis of prospective clinical trials //
JAMA - J. Am. Med. Assoc. 2009. Vol. 301, № 22. P. 2349–2361.
61.
Godley L.A., Larson R.A. Therapy-Related Myeloid Leukemia // Semin. Oncol. 2008.
Vol. 35, № 4. P. 418–429.
62.
Fenaux P. et al. Efficacy of azacitidine compared with that of conventional care regimens
in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label,
phase III study // Lancet Oncol. 2009. Vol. 10, № 3. P. 223–232.
63.
Craddock C. et al. Clinical activity of azacitidine in patients who relapse after allogeneic
stem cell transplantation for acute myeloid leukemia // Haematologica. 2016. Vol. 101, №
7. P. 879–883.
64.
Aldoss I. et al. Efficacy of the combination of venetoclax and hypomethylating agents in
relapsed/refractory acute myeloid leukemia // Haematologica. Ferrata Storti Foundation,
2018. Vol. 103, № 9. P. e404–e407.
65.
Rowe J.M. et al. A phase 3 study of three induction regimens and of priming with GM-
69
CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative
Oncology Group. // Blood. 2004. Vol. 103, № 2. P. 479–485.
66.
Pophali P., Litzow M. What Is the Best Daunorubicin Dose and Schedule for Acute
Myeloid Leukemia Induction? // Current Treatment Options in Oncology. 2017. Vol. 18,
№ 1. P. 3.
67.
Medeiros B.C. et al. Randomized study of continuous high-dose Lenalidomide, sequential
Azacitidine and Lenalidomide, or azacitidine in persons 65 years and over with newly-
diagnosed acute myeloid leukemia // Haematologica. Ferrata Storti Foundation, 2018.
Vol. 103, № 1. P. 101–106.
68.
Burnett A.K. et al. A comparison of low-dose cytarabine and hydroxyurea with or without
all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome
in patients not considered fit for intensive treatment. // Cancer. 2007. Vol. 109, № 6. P.
1114–1124.
69.
Cortes J.E. et al. Randomized comparison of low dose cytarabine with or without
glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk
myelodysplastic syndrome // Leukemia. Nature Publishing Group, 2019. Vol. 33, № 2. P.
379–389.
70.
Bell J.A. et al. Effectiveness and Safety of Therapeutic Regimens for Elderly Patients
With Acute Myeloid Leukemia: A Systematic Literature Review // Clin. Lymphoma,
Myeloma Leuk. 2018. Vol. 18, № 7. P. e303–e314.
71.
He P.-F. et al. Efficacy and safety of decitabine in treatment of elderly patients with acute
myeloid leukemia: A systematic review and meta-analysis // Oncotarget. 2017. Vol. 8, №
25. P. 41498–41507.
72.
Giles F. et al. Validation of the European Prognostic Index for younger adult patients with
acute myeloid leukaemia in first relapse // Br. J. Haematol. Blackwell Publishing Ltd,
2006. Vol. 134, № 1. P. 58–60.
73.
Thol F. et al. How I treat refractory and early relapsed acute myeloid leukemia // Blood.
2015. Vol. 126, № 3. P. 319–327.
74.
Craddock C. et al. Factors predicting outcome after unrelated donor stem cell
transplantation in primary refractory acute myeloid leukaemia // Leukemia. 2011. Vol. 25,
№ 5. P. 808–813.
75.
Fopp M. et al. Post-remission therapy of adult acute myeloid leukaemia: one cycle of
high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group
for Clinical Cancer Research (SAKK). // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 1997.
Vol. 8, № 3. P. 251–257.
70
76.
Hsu H.C. et al. Post-remission intensive consolidation with high-dose cytarabine-based
chemotherapy and granulocyte colony-stimulatory factor in adults with acute
myelogenous leukemia: a preliminary report. // Zhonghua Yi Xue Za Zhi (Taipei). 1995.
Vol. 56, № 5. P. 305–311.
77.
Frazer J. et al. Characteristics predicting outcomes of allogeneic Stem-Cell transplantation
in relapsed acute myelogenous leukemia // Curr. Oncol. 2017. Vol. 24, № 2. P. e123–
e130.
78.
Cruijsen M. et al. Clinical Results of Hypomethylating Agents in AML Treatment // J.
Clin. Med. 2014. Vol. 4, № 1. P. 1–17.
79.
Serve H. et al. Sorafenib in combination with intensive chemotherapy in elderly patients
with acute myeloid leukemia: Results from a randomized, placebo-controlled trial // J.
Clin. Oncol. American Society of Clinical Oncology, 2013. Vol. 31, № 25. P. 3110–3118.
80.
Boissel N. et al. Dasatinib in high-risk core binding factor acute myeloid leukemia in first
complete remission: A french acute myeloid leukemia intergroup trial // Haematologica.
Ferrata Storti Foundation, 2015. Vol. 100, № 6. P. 780–785.
81.
Rautenberg C. et al. Relapse of acute myeloid leukemia after allogeneic stem cell
transplantation: Prevention, detection, and treatment // International Journal of Molecular
Sciences. 2019. Vol. 20, № 1. P. 228.
82.
Mamez A.-C. et al. Pre-treatment with oral hydroxyurea prior to intensive chemotherapy
improves early survival of patients with high hyperleukocytosis in acute myeloid
leukemia. // Leuk. Lymphoma. 2016. Vol. 57, № 10. P. 2281–2288.
83.
Bakst R.L. et al. How I treat extramedullary acute myeloid leukemia // Blood. 2011. Vol.
118, № 14. P. 3785–3793.
84.
Chang A., Patel S. Treatment of Acute Myeloid Leukemia During Pregnancy // Annals of
Pharmacotherapy. 2015. Vol. 49, № 1. P. 48–68.
85.
Nakajima Y. et al. Acute leukemia during pregnancy: an investigative survey of the past
11 years // Int. J. Lab. Hematol. 2015. Vol. 37, № 2. P. 174–180.
86.
Selig B.P. et al. Cancer chemotherapeutic agents as human teratogens. // Birth Defects
Res. A. Clin. Mol. Teratol. 2012. Vol. 94, № 8. P. 626–650.
87.
Rolbin S.H. et al. Epidural anesthesia in pregnant patients with low platelet counts. //
Obstet. Gynecol. 1988. Vol. 71, № 6 Pt 1. P. 918–920.
88.
Salem M.N., Abbas A.M., Ashry M. Dexamethasone for the prevention of neonatal
respiratory morbidity before elective cesarean section at term // Proc. Obstet. Gynecol.
2016. Vol. 6, № 3. P. 1–10.
89.
López-Jiménez J. et al. Chemotherapy-induced nausea and vomiting in acute leukemia
71
and stem cell transplant patients: results of a multicenter, observational study. //
Haematologica. 2006. Vol. 91, № 1. P. 84–91.
90.
Kang K.-W. et al. Impact of G-CSF for Outcomes of Non-M3 AML Patients Who Were
Treated By Anthracycline-Based Induction (7+3 regimen) Chemotherapies // Blood. 2015.
Vol. 126, № 23. P. 4889–4889.
91.
Delforge M. et al. Recommended indications for the administration of polyclonal
immunoglobulin preparations // Acta Clin. Belg. 2011. Vol. 66, № 5. P. 346–360.
92.
Anderson D. et al. Guidelines on the use of intravenous immune globulin for hematologic
conditions. // Transfus. Med. Rev. 2007. Vol. 21, № 2 Suppl 1. P. S9-56.
93.
Blumberg N. et al. Platelet transfusion and survival in adults with acute leukemia //
Leukemia. Nature Publishing Group, 2008. Vol. 22, № 3. P. 631–635.
94.
Delaflor-Weiss E., Mintz P.D. The evaluation and management of platelet refractoriness
and alloimmunization // Transfus. Med. Rev. 2000. Vol. 14, № 2. P. 180–196.
95.
DeZern A.E. et al. Red blood cell transfusion triggers in acute leukemia: a randomized
pilot study // Transfusion. 2016. Vol. 56, № 7. P. 1750–1757.
96.
Szczepiorkowski Z.M., Dunbar N.M. Transfusion guidelines: when to transfuse. //
Hematology / the Education Program of the American Society of Hematology. American
Society of Hematology. Education Program. 2013. Vol. 2013. P. 638–644.
97.
Абузарова Г.Р. et al. Обезболивание взрослых и детей при оказании медицинской
помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И. Пирогова
Минздрава России., 2016. 94 p.
98.
Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies. // Am.
J. Phys. Med. Rehabil. 2011. Vol. 90, № 5 Suppl 1. P. S88-94.
99.
Baer M.R. et al. Cytarabine, Daunorubicin and Etoposide (ADE) Chemotherapy in Acute
Myeloid Leukemia (AML) Patients ≥60 Years (CALGB 9720). // Blood. American
Society of Hematology, 2007. Vol. 110, № 11. P. 296–296.
100. Bassan R., Barbui T. Remission induction therapy for adults with acute myelogenous
leukemia: towards the ICE age? // Haematologica. Vol. 80, № 1. P. 82–90.
101. Link H. et al. Mitoxantrone, cytosine arabinoside, and VP-16 in 36 patients with relapsed
and refractory acute myeloid leukemia. // Hamatol. Bluttransfus. 1990. Vol. 33. P. 322–
325.
102. Pastore D. et al. FLAG-IDA in the treatment of refractory/relapsed acute myeloid
leukemia: Single-center experience // Ann. Hematol. 2003. Vol. 82, № 4. P. 231–235.
103. Bishop J.F. et al. Intensified induction chemotherapy with high dose cytarabine and
etoposide for acute myeloid leukemia: A review and updated results of the Australian
72
leukemia study group // Leuk. Lymphoma. Informa Healthcare, 1998. Vol. 28, № 3–4. P.
315–327.
104. Reese N.D., Schiller G.J. High-dose cytarabine (HD araC) in the treatment of leukemias:
A review // Curr. Hematol. Malig. Rep. 2013. Vol. 8, № 2. P. 141–148.
105. Grigg A.P. et al. Prognostic features for response and survival in elderly patients wth de
novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine
// Leuk. Lymphoma. 2005. Vol. 46, № 3. P. 367–375.
106. Hiddemann W. et al. High-dose cytosine arabinoside and mitoxantrone (Ham) for the
treatment of refractory acute lymphoblastic leukemia // Oncol. Res. Treat. 1987. Vol. 10,
№ 1. P. 11–12.
107. Schlenk R.F. et al. Phase III study of all-trans retinoic acid in previously untreated patients
61 years or older with acute myeloid leukemia // Leukemia. Nature Publishing Group,
2004. Vol. 18, № 11. P. 1798–1803.
108. Heil G. et al. High-dose cytosine arabinoside and daunorubicin postremission therapy in
adults with de novo acute myeloid leukemia - Long-term follow-up of a prospective
multicenter trial // Ann. Hematol. Springer-Verlag, 1995. Vol. 71, № 5. P. 219–225.
109. Larson S.M. et al. High dose cytarabine and mitoxantrone: An effective induction regimen
for high-risk Acute Myeloid Leukemia (AML) // Leuk. Lymphoma. 2012. Vol. 53, № 3.
P. 445–450.
110. Röllig C. et al. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose
cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients // Ann. Oncol.
Oxford University Press, 2018. Vol. 29, № 4. P. 973–978.
111. Choi Y.W. et al. Oral maintenance chemotherapy with 6-Mercaptopurine and
methotrexate in patients with acute myeloid leukemia ineligible for transplantation // J.
Korean Med. Sci. Korean Academy of Medical Science, 2015. Vol. 30, № 10. P. 1416–
1422.
112. He P.F. et al. Efficacy and safety of decitabine in treatment of elderly patients with acute
myeloid leukemia: A systematic review and metaanalysis // Oncotarget. Impact Journals
LLC, 2017. Vol. 8, № 25. P. 41498–41507.
|